In animal models of cancer-induced bone pain, administration of MOTS-c enhanced the OPG/RANKL ratio, downregulated RANK, RANKL, and TRAP expression, and thereby inhibited osteoclastogenesis and bone degradation [26]. The gene discussed is TNFSF11; the disease is cancer.